Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/AAC.01521-20 http://scihub22266oqcxt.onion/10.1128/AAC.01521-20 32868327!7577145!32868327     free     free     free       Antimicrob+Agents+Chemother 2020 ; 64 (11): ? Nephropedia Template TP {{tp|p=32868327|t=2020. Removal of Remdesivir s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19 |pdf=|usr=}}{{32868327}} gab.com Text Removal of Remdesivir s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19 JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32868327 #FOAvip Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and sulfobutylether beta-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19). Twit Text FOAVip Removal of Remdesivir s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19 ????Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32868327 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32868327 #FOAvip English Wikipedia <ref>{{Cite pmid|32868327}}</ref> Removal of Remdesivir s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19 #MMPMID32868327 Le MP; Le Hingrat Q; Jaquet P; Wicky PH; Bunel V; Massias L; Visseaux B; Messika J; Descamps D; Mal H; Timsit JF; Peytavin G Antimicrob Agents Chemother 2020[Oct]; 64 (11): ? PMID32868327show ga Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and sulfobutylether beta-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19). |Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & derivatives/chemistry/metabolism[MESH] |Adenosine/analogs & derivatives[MESH] |Alanine/administration & dosage/adverse effects/*analogs & derivatives/chemistry/metabolism[MESH] |Antiviral Agents/*administration & dosage/adverse effects/chemistry/metabolism[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/drug therapy/surgery/*therapy/virology[MESH] |Drug Interactions[MESH] |Furans/adverse effects/chemistry/*urine[MESH] |Humans[MESH] |Intensive Care Units[MESH] |Lung Transplantation[MESH] |Multiple Organ Failure[MESH] |Pandemics[MESH] |Pneumonia, Viral/surgery/*therapy/virology[MESH] |Pyrroles/adverse effects/chemistry/*urine[MESH] |Renal Dialysis[MESH] |SARS-CoV-2[MESH] |Transplant Recipients[MESH] |Triazines/adverse effects/chemistry/*urine[MESH]Removal of Remdesivir s Metabolite GS-441524 by Hemodialysis in a Doub(epmc).pdf DeepDyve Pubget Overpricing